UNIVERSITY OF WASHINGTON
đşđ¸United States
- Country
- đşđ¸United States
- Ownership
- Private
- Established
- 1861-01-01
- Employees
- 10K
- Market Cap
- -
Early Intervention in Pulmonary Exacerbation in Cystic Fibrosis
Not Applicable
Completed
- Conditions
- Cystic Fibrosis
- Interventions
- Other: Early Intervention
- First Posted Date
- 2009-02-25
- Last Posted Date
- 2016-12-01
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 42
- Registration Number
- NCT00850551
- Locations
- đşđ¸
University of Washington, Seattle, Washington, United States
Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma
Phase 1
Terminated
- Conditions
- Refractory Multiple MyelomaStage I Multiple MyelomaStage II Multiple MyelomaStage III Multiple Myeloma
- Interventions
- First Posted Date
- 2009-02-23
- Last Posted Date
- 2017-09-08
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 31
- Registration Number
- NCT00849251
- Locations
- đşđ¸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant
Phase 1
Completed
- Conditions
- Localized Unresectable Adult Primary Liver CancerLocalized Resectable Adult Primary Liver CancerAdult Primary Hepatocellular CarcinomaAdvanced Adult Primary Liver CancerRecurrent Adult Primary Liver Cancer
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2009-02-16
- Last Posted Date
- 2015-03-27
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 4
- Registration Number
- NCT00844168
- Locations
- đşđ¸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Oral T7 Oral Testosterone in Man
Phase 2
Completed
- Conditions
- Healthy MalesMale Contraceptive
- Interventions
- Drug: First Intervention (7 days)Drug: Second Intervention (7 days)Drug: Third Intervention (7 days)Other: First Washout (7 days)Other: Second wash-out period
- First Posted Date
- 2009-02-12
- Last Posted Date
- 2014-01-13
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 11
- Registration Number
- NCT00842751
- Locations
- đşđ¸
University of Washington, Seattle, Washington, United States
HOP-3 Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone
Phase 1
Completed
- Conditions
- Healthy Males
- Interventions
- Other: placebo hCG (no active ingredient)
- First Posted Date
- 2009-02-09
- Last Posted Date
- 2016-01-11
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 59
- Registration Number
- NCT00839319
- Locations
- đşđ¸
University of Washington, Seattle, Washington, United States
Peripheral Immunologic Response of Solid Organ Transplant Recipients to Depletion Versus Non-depletion Protocols
Completed
- Conditions
- Liver DiseaseLiver Transplantation
- Interventions
- Procedure: blood sampling
- First Posted Date
- 2009-02-09
- Last Posted Date
- 2011-03-03
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 30
- Registration Number
- NCT00839709
- Locations
- đşđ¸
University of Washington, Seattle, Washington, United States
The Medication Adherence Program
Not Applicable
- Conditions
- TreatmentDiabetes
- Interventions
- Other: Medication Adherence Program (MAP)
- First Posted Date
- 2009-02-06
- Last Posted Date
- 2009-09-30
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 240
- Registration Number
- NCT00838344
- Locations
- đşđ¸
University of Washington, Seattle, Washington, United States
Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma
Phase 2
Completed
- Conditions
- Adult Anaplastic AstrocytomaAdult Anaplastic OligodendrogliomaAdult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaRecurrent Adult Brain Neoplasm
- Interventions
- Other: Quality-of-Life Assessment
- First Posted Date
- 2009-01-16
- Last Posted Date
- 2017-07-07
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 45
- Registration Number
- NCT00823797
- Locations
- đşđ¸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
đşđ¸Northwestern University, Chicago, Illinois, United States
đşđ¸Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer
Phase 2
Completed
- Conditions
- Skin MetastasesRecurrent Breast CancerMale Breast CancerStage IV Breast Cancer
- Interventions
- Other: laboratory biomarker analysisGenetic: RNA analysisOther: immunoenzyme technique
- First Posted Date
- 2009-01-14
- Last Posted Date
- 2018-01-02
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 15
- Registration Number
- NCT00821964
- Locations
- đşđ¸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Immunomodulation Following Transfusion
Phase 4
Completed
- Conditions
- Blood Component Transfusion
- Interventions
- Biological: Standard blood componentsBiological: Leukoreduced blood componentsBiological: Leukoreduced and irradiated
- First Posted Date
- 2008-12-18
- Last Posted Date
- 2017-12-26
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 287
- Registration Number
- NCT00810810
- Locations
- đşđ¸
University of Washington Medical Center, Seattle, Washington, United States
đşđ¸Northwest Hospital, Seattle, Washington, United States
Š Copyright 2025. All Rights Reserved by MedPath